20516562

Source:http://linkedlifedata.com/resource/pubmed/id/20516562

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0015219, umls-concept:C0017431, umls-concept:C0019682, umls-concept:C0019699, umls-concept:C0030946, umls-concept:C0205195, umls-concept:C0521115, umls-concept:C0754188, umls-concept:C1145759, umls-concept:C1533691, umls-concept:C1705294
pubmed:issue	3
pubmed:dateCreated	2010-6-2
pubmed:abstractText	The pathways of resistance to atazanavir (ATV) and amprenavir (APV) converge at position 50 of HIV protease. The determinants of cross-resistance were analysed during in vitro sequential or concomitant combination pressure with both drugs.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9815705
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Carbamates, http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease, http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/amprenavir, http://linkedlifedata.com/resource/pubmed/chemical/atazanavir, http://linkedlifedata.com/resource/pubmed/chemical/p16 protease, Human...
pubmed:status	MEDLINE
pubmed:issn	2040-2058
pubmed:author	pubmed-author:BlancoJuliáJ, pubmed-author:BofillMargaritaM, pubmed-author:CabreraCeciliaC, pubmed-author:ClotetBonaventuraB, pubmed-author:CunyatFrancescF, pubmed-author:MarfilSilviaS, pubmed-author:PuigTeresaT, pubmed-author:RuizLidiaL
pubmed:issnType	Electronic
pubmed:volume	15
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	431-6
pubmed:meshHeading	pubmed-meshheading:20516562-Carbamates, pubmed-meshheading:20516562-Cell Line, pubmed-meshheading:20516562-Drug Administration Schedule, pubmed-meshheading:20516562-Drug Resistance, Viral, pubmed-meshheading:20516562-Drug Therapy, Combination, pubmed-meshheading:20516562-Evolution, Molecular, pubmed-meshheading:20516562-Genotype, pubmed-meshheading:20516562-HIV Infections, pubmed-meshheading:20516562-HIV Protease, pubmed-meshheading:20516562-HIV Protease Inhibitors, pubmed-meshheading:20516562-HIV-1, pubmed-meshheading:20516562-Humans, pubmed-meshheading:20516562-Oligopeptides, pubmed-meshheading:20516562-Phenotype, pubmed-meshheading:20516562-Pyridines, pubmed-meshheading:20516562-Recombination, Genetic, pubmed-meshheading:20516562-Sulfonamides, pubmed-meshheading:20516562-Treatment Failure
pubmed:year	2010
pubmed:articleTitle	Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
pubmed:affiliation	Fundació irsiCaixa, Institut de Recerca en Ciències de la Salut Germans Trias I Pujol, Hospital Germans Trias, Universitat Autònoma de Barcelona, Badalona, Barcelona, Catalonia, Spain.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't